Torna all'elenco degli studi

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)

CODICE STUDIO

NCT05623020

TIPOLOGIA

Prima linea anziani

NOME SPONSOR

Pfizer

DESCRIZIONE

Trattamento

Experimental: Arm A: Teclistamab-Lenalidomide (Tec-Len)

Experimental: Part 1, Multiple Dose Levels, Elranatamab + Daratumumab + Lenalidomide :

Experimental: Part 2 Randomized Arm A: Elranatamab + Daratumumab + Lenalidomide :

Active Comparator: Part 2 Randomized Arm B: Daratumumab + Lenalidomide + Dexamethasone :

Leggi tutto

FARMACI UTILIZZATI

Belantamab Mafodotin, Bortezomib (velcade), Ciclofosfamide, Ciltacabtagene autoleucel CAR-T